echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Hansoh Pharma Announces Clinical Data of PI3Kα Inhibitor

    Hansoh Pharma Announces Clinical Data of PI3Kα Inhibitor

    • Last Update: 2022-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, at the 113th American Association for Cancer Research (AACR) annual meeting in 2022, Hansoh Pharma announced the research data of the single-agent phase I ramp-up trial of its self-developed class 1 innovative drug PI3Kα inhibitor HS-10352-101


    This report was presented by Prof.


    So far, China has not approved any PIK3CA inhibitors for marketing


    The full name of PI3K is phosphatidylinositol-3-kinase, which is an important signaling pathway in cells and one of the key targets for the development of new anti-tumor drugs in recent years


    According to the Insight database, there are a total of 36 PI3Kα projects under research in the world, of which 2 have been approved for marketing and 3 are in Phase III clinical trials


    PI3Kα target details

    From: Insight Database

    Edit: plus one

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.